Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Cope, Shannon ^a   Zhang, Jie ^b   Williams, James ^b   Jansen, Jeroen P ^a  

^a MAPI Consultancy   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ARTICLE; BAYES THEOREM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; META ANALYSIS; TREATMENT RESPONSE;

ADRENERGIC BETA-2 RECEPTOR ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOLAMINES; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 84862590550     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-29     Document Type: Article

References (45)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease 2010, http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html, Global Initiative for Chronic Obstructive Lung Disease (GOLD).
2. Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2009, 29:891-905. 10.1592/phco.29.8.891, 19637942.
3. Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009, 7:2. 10.1186/1741-7015-7-2, 2636836, 19144173.
4. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices-Part 2. Value Health 2011, 14:1429-1437.
5. Jansen JP. Network meta-analysis of individual and aggregate level data 2012, under review.
6. Dogra A, Peckitt C, Clay M, Lassen C, Kramer B. Study number QAB149B2354: A 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease 2010,
7. Dogra A, Henley M, Clay M, Lassen C, Kramer B. Study number QAB149B2355: A 12-week treatment, multi-center, randomized, doubleblind, placebo-controlled, parallel-group study to assess the efficacy and safety of once daily indacaterol in patients with chronic obstructive pulmonary disease 2010,
8. Dahl R, Fan C, Chung K, Buhl R. Efficacy of a new once-daily long-acting inhaled formoterol in COPD b2-agonist indacaterol versus twice-daily. Thorax 2010, 65:473-479. 10.1136/thx.2009.125435, 20522841.
9. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B. INHANCE study investigators: Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162. 10.1164/rccm.200910-1500OC, 20463178.
10. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B. INLIGHT-2 study investigators: Once-daily indacaterol vs. twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37(2):273-279. 10.1183/09031936.00045810, 20693243.
11. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgens M, Kramer B. INLIGHT 1 study group: Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11. 10.1186/1471-2466-10-11, 2848004, 20211002.
12. Cope S, Capkun-Niggli G, Gale R, Jardim J, Jansen JP. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease - a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011, 6:329-344. 3119108, 21697997.
13. Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health Care Evaluation 2004, Chichester, UK: Wiley.
14. Sutton AJ, Abrams KR, Jones DR. Methods for Meta-Analysis in Medical Research 2000, Chichester, UK: Wiley.
15. Jansen JP, Crawford B, Bergman G, Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11:956-964. 10.1111/j.1524-4733.2008.00347.x, 18489499.
16. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 2011, 14:417-428. 10.1016/j.jval.2011.04.002, 21669366.
17. Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009, 28:1861-1881. 10.1002/sim.3594, 19399825.
18. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900. 10.1136/bmj.331.7521.897, 1255806, 16223826.
19. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124. 10.1002/sim.1875, 15449338.
20. Brooks SP, Gelman A. General Methods for Monitoring Convergence of Iterative Simulations. J Comput Graph Stat 1998, 7:434-455.
21. Briggs DD, Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005, 18:397-404. 10.1016/j.pupt.2005.02.013, 16179215.
22. Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale BCSS. Respir Med 2003, 97(A):S35-S43.
23. Covelli H, Bhattacharya S, Cassino C, Conoscenti C, Kesten S. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005, 25:1708-1718. 10.1592/phco.2005.25.12.1708, 16305289.
24. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della Cioppa G. Formoterol in Chronic Obstructive Pulmonary Disease I Study Group: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
25. Gross N, Nelson H, Lapidus R, Dunn L, Lynn L, Rinehart M, Denis-Mize K. Formoterol Study Group: Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med 2008, 102:189-197. 10.1016/j.rmed.2007.10.007, 18363201.
26. Hanania N, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 mug)/salmeterol (50 mug) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843. 10.1378/chest.124.3.834, 12970006.
27. Mahler D, Wire P, Horstman D, Chang C, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J of Respir Crit Care Med 2002, 166:1084-1091.
28. Moita J, Bbrbara C, Cardoso J, Costa R, Sousa M, Ruiz J, Santos ML. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008, 21:146-151. 10.1016/j.pupt.2007.04.003, 17693107.
29. Niewoehner D, Rice K, Cote C, Paulson D, Cooper J, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005, 143:317-326.
30. Rossi A, Kristufek P, Levine B, Thomson M, Till D, Kottakis Della Cioppa G. FICOPD II Study Group: Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002, 121:1058-1069. 10.1378/chest.121.4.1058, 11948033.
31. Tonnel AB, Perez T, Grosbois JM, Verkindre C, Bravo ML, Brun M, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:301-310. 2629970, 18686739.
32. Van R, Roos B, Van N. An empirical comparison of the St George's Respiratory Questionnaire SGRQ and the Chronic Respiratory Disease Questionnaire CRQ in a clinical trial setting. Thorax 1999, 54:995-1003. 10.1136/thx.54.11.995, 1745382, 10525558.
33. Verkindre C, Bart F, Aguilaniu B, Fortin F, Guqrin JC, Le Merre C, Lacono P, Huchon G. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration 2006, 73:420-427. 10.1159/000089655, 16484769.
34. Chan C, Maltais F, Sigouin C, Haddon J, Ford G. SAFE Study Group: A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007, 14:465-472. 2677771, 18060091.
35. Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000, 118:1294-1302. 10.1378/chest.118.5.1294, 11083677.
36. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002, 19:217-224. 10.1183/09031936.02.00269802, 11866001.
37. Jones PW. St George's Respiratory Questionnaire. MCID. COPD 2005, 2:75-79.
38. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122(1):47-55. 10.1378/chest.122.1.47, 12114338.
39. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803. 10.1183/09031936.00191810, 21622587.
40. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048. 10.1185/03007990903103006, 19569976.
41. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469. 10.1183/09031936.00099306, 18238951.
42. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008, 63:831-838. 10.1136/thx.2007.086041, 18728206.
43. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999, 58(Suppl 4):25-33.
44. Tamura G, Ohta K. Adherence to treatment by patients with asthma or COPD: comparison between inhaled drugs and transdermal patch. Respir Med 2007, 101:1895-1902. 10.1016/j.rmed.2007.05.001, 17587559.
45. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011, 105:435-441. 10.1016/j.rmed.2010.09.006, 20880687.